<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2456">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542502</url>
  </required_header>
  <id_info>
    <org_study_id>HM14079</org_study_id>
    <nct_id>NCT01542502</nct_id>
  </id_info>
  <brief_title>Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, double-blind, crossover pilot study to measure the safety and
      feasibility of Interleukin-1 (IL-1) blockade with Anakinra in patients with stable heart
      failure with preserved ejection fraction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Peak Oxygen Consumption (Peak VO2)</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary endpoint is the change in peak oxygen consumption among stable heart failure patients (n = 12) following 14-days treatment with daily doses of Anakinra 100 mg (SC, subcutaneous).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilatory Efficiency (VE/VCO2 [Carbon Dioxide] Slope)</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Interval change from baseline in ventilatory efficiency (VE/VCO2 slope) upon completion of 2 weeks treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Time</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Interval change from baseline in exercise time upon completion of 2 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Biomarkers</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Interval change from baseline in high-sensitivity C-reactive protein upon completion of 2 weeks treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Symptoms (DASI)</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Interval change from baseline in Heart Failure (HF) symptoms as measured by Duke Activity Status Index (DASI) upon completion of 2 weeks treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary endpoints will include assessment of adverse events and hospitalizations during 4-week duration of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Endpoints</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation between interval change in peak VO2 and high sensitivity C-reactive protein</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with daily subcutaneous injections of Anakinra 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with daily subcutaneous injection of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>Anakinra 100 mg daily subcutaneous injection</description>
    <arm_group_label>Anakinra</arm_group_label>
    <other_name>Recombinant human Interleukin-1 receptor antagonist</other_name>
    <other_name>Kineret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium Chloride (NaCl) 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms and signs of congestive heart failure

          -  Recent Imaging Study (&lt;12 months) showing Left Ventricular Ejection Fraction (LVEF)
             &gt;50% and Left Ventricular End Diastolic Volume Index (LVEDVI) &lt;97ml/m2

          -  Evidence of abnormal Left Ventricular (LV) relaxation, filling, diastolic
             distensibility, and diastolic stiffness as shown by one of the following:

               1. Invasive Hemodynamic measurements

                    -  mean Pulmonary Capillary Wedge pressure (mPCW) &gt;12

                    -  Left Ventricular End Diastolic Pressure (LVEDP) &gt;16 mmHg

               2. Tissue Doppler Echocardiogram

                    -  E/E' &gt;15

                    -  E/E' 8-15 and one of the following

                         -  Left Ventricular Hypertrophy (LVH)

                         -  Atrial Fibrillation

                         -  Left Atrial Enlargement

                         -  E/A &lt;0.5 + Deceleration Time (DT) &gt;280 (if &gt;50yrs of age)

               3. Biomarkers

          -  Brain Natriuretic Peptide (BNP) &gt;200pg/mL

        Exclusion Criteria:

          -  Age &lt;18

          -  Recent changes (previous 3 months) in HF maintenance medications (beta-blockers,
             angiotensin converting enzyme [ACE] inhibitors, aldosterone antagonists,
             vasodilators, cardiac glycosides, diuretics)

          -  Hospitalization for worsening Heart Failure (HF) or acute decompensated HF within the
             previous 12months

          -  Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable
             cardioverter defibrillator (AICD)

          -  Angina or electrocardiograph (ECG) changes that limit maximum exertion during
             cardiopulmonary exercise testing

          -  Active infection including chronic infection

          -  Active cancer

          -  Recent (&lt;14 days) use of anti-inflammatory drugs (not including Non-Steroidal
             Anti-Inflammatory Drugs [NSAIDs]), Chronic inflammatory disorder (including but not
             limited to rheumatoid arthritis, systemic lupus erythematosus), malignancy, or any
             comorbidity limiting survival or ability to complete the study

          -  Pregnancy (determined by urine pregnancy test in women of childbearing potential)

          -  Inability to give informed consent

          -  Other conditions limiting completion of cardiopulmonary exercise test or completion
             of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 4, 2016</lastchanged_date>
  <firstreceived_date>February 23, 2012</firstreceived_date>
  <firstreceived_results_date>August 19, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure with preserved ejection fraction</keyword>
  <keyword>Diastolic heart failure</keyword>
  <keyword>Aerobic exercise performance</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Anakinra (First) Then Placebo (Second)</title>
          <description>Treatment with daily subcutaneous injections of Anakinra 100 mg for 14 days, followed by daily subcutaneous injections of Placebo for 14 days
Anakinra: Anakinra 100 mg daily subcutaneous injection Placebo: Placebo daily subcutaneous injection</description>
        </group>
        <group group_id="P2">
          <title>Placebo (First) Then Anakinra (Second)</title>
          <description>Treatment with daily subcutaneous injections of Placebo for 14 days, followed by daily subcutaneous injections of Anakinra for 14 days
Placebo: Placebo daily subcutaneous injection Anakinra: Anakinra 100 mg daily subcutaneous injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is a cross-over trial, so all patients have been treated with anakinra and with placebo at different times.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Baseline measures for all study participants</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61" lower_limit="55" upper_limit="64"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Oxygen Consumption (Peak VO2)</title>
        <description>The primary endpoint is the change in peak oxygen consumption among stable heart failure patients (n = 12) following 14-days treatment with daily doses of Anakinra 100 mg (SC, subcutaneous).</description>
        <time_frame>14 days</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Anakinra</title>
            <description>Treatment with daily subcutaneous injections of Anakinra 100 mg
Anakinra: Anakinra 100 mg daily subcutaneous injection</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treatment with daily subcutaneous injection of placebo
Placebo: Placebo daily subcutaneous injection</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Peak Oxygen Consumption (Peak VO2)</title>
            <description>The primary endpoint is the change in peak oxygen consumption among stable heart failure patients (n = 12) following 14-days treatment with daily doses of Anakinra 100 mg (SC, subcutaneous).</description>
            <units>ml*kg^-1*min^-1</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" lower_limit="0.6" upper_limit="2.3"/>
                  <measurement group_id="O2" value="-0.1" lower_limit="-0.5" upper_limit="1.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.009</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilatory Efficiency (VE/VCO2 [Carbon Dioxide] Slope)</title>
        <description>Interval change from baseline in ventilatory efficiency (VE/VCO2 slope) upon completion of 2 weeks treatment.</description>
        <time_frame>14 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Time</title>
        <description>Interval change from baseline in exercise time upon completion of 2 weeks treatment</description>
        <time_frame>14 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Biomarkers</title>
        <description>Interval change from baseline in high-sensitivity C-reactive protein upon completion of 2 weeks treatment.</description>
        <time_frame>28 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Failure Symptoms (DASI)</title>
        <description>Interval change from baseline in Heart Failure (HF) symptoms as measured by Duke Activity Status Index (DASI) upon completion of 2 weeks treatment.</description>
        <time_frame>28 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Secondary endpoints will include assessment of adverse events and hospitalizations during 4-week duration of study.</description>
        <time_frame>28 days</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Endpoints</title>
        <description>Correlation between interval change in peak VO2 and high sensitivity C-reactive protein</description>
        <time_frame>28 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Anakinra</title>
          <description>Treatment with daily subcutaneous injections of Anakinra 100 mg
Anakinra: Anakinra 100 mg daily subcutaneous injection</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Treatment with daily subcutaneous injection of placebo
Placebo: Placebo daily subcutaneous injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reactions</sub_title>
                <description>Mild injection site reaction - not requiring cessation of therapy</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a pilot study to estimate the effects of targeted anti-inflammatory treatment on aerobic exercise capacity in patients with Heart Failure and Preserved Ejection Fraction. All findings should therefore be considered hypothesis generating.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Antonio Abbate</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-0513</phone>
      <email>aabbate@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
